Literature DB >> 17335676

Alcoholic steatohepatitis: management and prognosis.

Jacquelyn J Maher1.   

Abstract

Alcoholic hepatitis is a disease with a wide range of severity. Patients with severe disease have short-term mortality rates above 35%. In these high-risk patients, pharmacologic therapy is an important adjunct to supportive medical care and has been proved to improve survival. Given the benefit of drug treatment, it is important to identify patients at risk of early mortality from alcoholic hepatitis. A number of validated scoring systems are useful for this purpose, including the Maddrey Discriminant Function, the Model of End-Stage Liver Disease score, and the Glasgow Alcoholic Hepatitis score. Patients judged by one or more of these criteria to have severe alcoholic hepatitis should be treated with corticosteroids or pentoxifylline, provided they have no contraindications for this treatment. Adequate nutrition is also critical and should be provided by tube feeding if necessary. A prompt decline in serum bilirubin indicates a favorable response to therapy. Patients who do not exhibit a reduction in serum bilirubin within 1 week are considered nonresponders and have a 6-month mortality rate of 50% or higher.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17335676     DOI: 10.1007/s11894-008-0019-6

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  43 in total

1.  Effects of corticosteroids on HCV infection.

Authors:  N Magy; B Cribier; C Schmitt; B Ellero; D Jaeck; K Boudjema; P Wolf; N Labouret; M Doffoel; A Kirn; F Stoll-Keller
Journal:  Int J Immunopharmacol       Date:  1999-04

2.  Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis.

Authors:  H Orrego; J E Blake; L M Blendis; A Medline
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

3.  Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone.

Authors:  C L Mendenhall; S Anderson; P Garcia-Pont; S Goldberg; T Kiernan; L B Seeff; M Sorrell; C Tamburro; R Weesner; R Zetterman
Journal:  N Engl J Med       Date:  1984-12-06       Impact factor: 91.245

4.  MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis.

Authors:  Wichit Srikureja; Namgyal L Kyulo; Bruce A Runyon; Ke-Qin Hu
Journal:  J Hepatol       Date:  2005-05       Impact factor: 25.083

5.  Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.

Authors:  E Akriviadis; R Botla; W Briggs; S Han; T Reynolds; O Shakil
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

6.  Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis.

Authors:  Herbert Tilg; Rajiv Jalan; Arthur Kaser; Nathan A Davies; Felix A Offner; Stephen J Hodges; Othmar Ludwiczek; Deborah Shawcross; Heinz Zoller; Akeel Alisa; Rajeshwar P Mookerjee; Ivo Graziadei; Christian Datz; Michael Trauner; Detlef Schuppan; Peter Obrist; Wolfgang Vogel; Roger Williams
Journal:  J Hepatol       Date:  2003-04       Impact factor: 25.083

7.  ESPEN Guidelines on Enteral Nutrition: Liver disease.

Authors:  M Plauth; E Cabré; O Riggio; M Assis-Camilo; M Pirlich; J Kondrup; P Ferenci; E Holm; S Vom Dahl; M J Müller; W Nolte
Journal:  Clin Nutr       Date:  2006-05-16       Impact factor: 7.324

8.  A randomized trial of prednisolone in patients with severe alcoholic hepatitis.

Authors:  M J Ramond; T Poynard; B Rueff; P Mathurin; C Théodore; J C Chaput; J P Benhamou
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245

9.  Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial.

Authors:  R L Carithers; H F Herlong; A M Diehl; E W Shaw; B Combes; H J Fallon; W C Maddrey
Journal:  Ann Intern Med       Date:  1989-05-01       Impact factor: 25.391

Review 10.  Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence.

Authors:  Michael Charlton
Journal:  Liver Transpl       Date:  2003-11       Impact factor: 5.799

View more
  1 in total

1.  Treatment of alcoholic liver disease.

Authors:  Thomas H Frazier; Abigail M Stocker; Nicole A Kershner; Luis S Marsano; Craig J McClain
Journal:  Therap Adv Gastroenterol       Date:  2011-01       Impact factor: 4.409

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.